Hills Bank & Trust Co Purchases New Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Hills Bank & Trust Co purchased a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,027,830 shares of the company’s stock, valued at approximately $13,722,000. Perspective Therapeutics makes up approximately 1.0% of Hills Bank & Trust Co’s holdings, making the stock its 21st biggest holding.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Perspective Therapeutics in the 1st quarter worth approximately $15,511,000. Affinity Asset Advisors LLC purchased a new stake in Perspective Therapeutics in the 1st quarter worth approximately $6,069,000. Nicholson Wealth Management Group LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter worth approximately $21,390,000. Finally, Ally Bridge Group NY LLC purchased a new stake in Perspective Therapeutics in the 2nd quarter worth approximately $3,951,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $11.80 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $2.20 and a 1 year high of $19.05. The company’s 50-day simple moving average is $13.52.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. As a group, research analysts forecast that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Bank of America initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective on the stock. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Perspective Therapeutics in a research report on Thursday, October 24th. Finally, Oppenheimer restated an “outperform” rating and set a $22.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 11th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $20.63.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.